Drug Topics Newsletter

To view this email as a web page, click here.

PHARMACISTS' REPORT

Tibsovo Indication Expanded to Newly-Diagnosed Acute Myeloid Leukemia

Tibsovo (ivosidenib) is an isocitrate dehydrogenase1-inhibitor, originally approved in 2018.

Kidney Disease Patients May Not Be Getting OACs

Many kidney disease patients with atrial fibrillation are not being treated with anticoagulation, increasing their risk of stroke.

Facial Recognition for Pharmacy Software

Liberty Software is reducing the burdens of security by introducing facial recognition for biometric security. Improve security and accountability while reducing the number of manual steps to achieve it.

What The World Might Look Like Without Rebates

Rebates for prescription drugs are under scrutiny and attacked in both the political and healthcare arenas. But what will happen if they go away?

Harnessing Technology to Enhance Diabetes Management

The most effective strategy is matching the technology to the patient.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.